Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

Journal of Clinical Oncology

Volumn 20, Issue 21, 2002, Pages 4319-4323

  Rajkumar, S Vincent ^a   Hayman, Suzanne ^a   Gertz, Morie A ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Greipp, Philip R ^a   Geyer, Susan ^a   Iturria, Nancy ^a   Fonseca, Rafael ^a   Lust, John A ^a   Kyle, Robert A ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CAUSE OF DEATH; CLINICAL ARTICLE; CONSTIPATION; CRYOPRESERVATION; DEEP VEIN THROMBOSIS; DEPRESSION; DYSPNEA; EDEMA; FEMALE; HEART ARRHYTHMIA; HUMAN; INFECTION; INNER EAR DISEASE; LUNG EMBOLISM; MALE; MULTIPLE MYELOMA; NEUROPATHY; PANCREATITIS; PRIORITY JOURNAL; RASH; SEDATION; STEM CELL TRANSPLANTATION; SYNCOPE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSTIPATION; DEXAMETHASONE; DYSPNEA; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; VENOUS THROMBOSIS;

EID: 0036843032     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.116     Document Type: Article

References (37)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000
2. Bataille R, Harousseau JL: Multiple myeloma. N Engl J Med 336:1657-1664, 1997
3. Vacca A, Ribatti D, Roncali L, et al: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87:503-508, 1994
4. Rajkumar SV, Leong T, Roche PC, et al: Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6:3111-3116, 2000
5. Rajkumar SV, Witzig TE: A review of angiogenesis and anti-angiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26:351-362, 2000
6. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
7. Rajkumar SV, Fonseca R, Dispenzieri A, et al: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75:897-902, 2000
8. Harousseau JL, Attal M: The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 34:61-66, 1997
9. Barlogie B, Jagannath S, Epstein J, et al: Biology and therapy of multiple myeloma in 1996. Semin Hematol 34:67-72, 1997
10. Gertz MA, Pineda AA, Chen MG, et al: Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci 309:152-161, 1995
11. Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86-89, 1990
12. Barlogie B, Jagannath S, Desikan KR, et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999
13. Alexanian R, Dimopoulos MA, Delasalle K, et al: Primary dexamethasone treatment of multiple myeloma. Blood 80:887-890, 1992
14. Alexanian R, Barlogie B, Dixon D: High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 105:8-11, 1986
15. Weber DM, Gavino M, Delasalle K, et al: Thalidomide alone or with dexamethasone for multiple myeloma. Blood 94:604a, 1999 (suppl 1, abstr)
16. Rajkumar SV, Gertz MA, Witzig TE: Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 343:972-973, 2000
17. Argiles JM, Carbo N, Lopez-Soriano FJ: Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? Med Hypotheses 50:313-318, 1998
18. Parman T, Wiley MJ, Wells PG: Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585, 1999
19. Iyer CG, Languillon J, Ramanujam K, et al: WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 45:719-732, 1971
20. Rajkumar SV, Fonseca R, Witzig TE, et al: Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13:469-472, 1999
21. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
22. Kneller A, Raanani P, Hardan I, et al: Therapy with thalidomide in refractory multiple myeloma: The revival of an old drug. Br J Haematol 108:391-393, 2000
23. Juliusson G, Celsing F, Turesson I, et al: Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109:89-96, 2000
24. Rajkumar SV, Dispenzieri A, Fonseca R, et al: Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 15:1274-1276, 2001
25. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
26. Zangari M, Anaissie E, Barlogie B, et al: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615, 2001
27. Osman K, Comenzo R, Rajkumar SV: Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951-1952, 2001
28. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
29. Lansink M, Koolwijk P, van Hinsbergh V, et al: Effect of steroid hormones and retinoids on the formation of capillary-like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression. Blood 92:927-938, 1998
30. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
31. Kenyon BM, Browne F, D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971-978, 1997
32. Or R, Feferman R, Shoshan S: Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol 26:217-221, 1998
33. Moreira AL, Sampaio EP, Zmuidzinas A, et al: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680, 1993
34. Haslett PA, Corral LG, Albert M, et al: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885-1892, 1998
35. Geitz H, Handt S, Zwingenberger K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213-221, 1996
36. Keifer JA, Guttridge DC, Ashburner BP, et al: Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382-22387, 2001
37. Majumdar S, Lamothe B, Aggarwal BB: Thalidomide suppresses NF-kappaB activation induced by TNF and H(2)O(2), but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 168:2644-2651, 2002